It is now recognized worldwide that anticipation and prevention of diseases have significant advantages for the health and healthy ageing of the population. Early recognition of the disease in a vulnerable population such as in children aged <5 years and adults aged >60 years enhances our preparedness for any eventualities and future burden of the diseases to society. It is also recognized that current public health practices alone cannot bring about the desired outcome. When tackling public health-related issues, such problems must be recognized and state-of-the-art principles and innovations from genomic sciences, information technologies, and medical specialties must be encompassed and embraced. These will enhance strategies for preparedness and provide us with a better understanding of how to identify, manage, and control disease burdens. The ever expanding landscape of genomics research also includes experimental and computational approaches for effectively utilizing DNA sequence information. From these perspectives, the intricacies of Mendelian single gene disorders are the least challenging compared to intricacies of multi-dimensional host factors for infectious diseases or complex disorders such as cancer. The concepts of public health in India are on firm footing; however, integration of contemporary advances to implement public health principles into practice has neither been attempted nor impacted on disease burden or our preparedness to prevent eventualities. At the same time, translational genomics is gradually paving the way for personalized medicine. Principles of personalized medicine remain to be fully understood and practiced despite the pharmacogenomics-based future of drug development, and treatment has not been as exciting as the advances in genomics we are witnessing today. The relevance, importance, and translational impediments of these advances will be discussed.

Keywords:
Genetics, India, Public health, Translational genomics
1.
Collins F, Green E, Guttmacher A, Guyer M: A vision for the future of genomics research. Nature 2003;422:835-847.
2.
Khoury M, Gwinn M, Yoon P, Dowling N, Moore C, et al: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665-674.
3.
Spear B, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201-204.
4.
de Lecea MG, Rossbach M: Translational genomics in personalized medicine - scientific challenges en route to clinical practice. Hugo J 2012;6:2.
5.
Chakrabarti B, Kumar S, Singh R, Dimitrova N: Genetic diversity and admixture patterns in Indian populations. Gene 2012;508:250-255.
6.
Indian Genome Variation Consortium: Genetic landscape of the people of India: a canvas for disease gene exploration. J Genet 2008;87:3-20.
7.
Tamang R, Thangaraj K: Genomic view on the peopling of India. Investig Genet 2012;3:20.
8.
Rajkumar R, Kashyap VK: Genetic structure of four socio-culturally diversified caste populations of southwest India and their affinity with related Indian and global groups. BMC Genet 2004;5:23.
9.
Verma IC: Burden of genetic disorders in India. Indian J Pediatr 2000;67:893-898.
10.
Verma IC, Puri RD: Global burden of genetic disease and the role of genetic screening. Semin Fetal Neonatal Med 2015;pii:S1744.
11.
Mohanty D, et al: Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Commun Genet 2013;1 33-42.
12.
Colah R, Mukherjee M, Ghosh K: Sickle cell disease in India. Curr Opin Hematol 2014;21:215-223.
13.
Rao VR: Community genetics approaches in the prevention of beta-thalassemia: towards achieving ‘Zero beta-thalassemia' status in India. Mol Cytogenet 2014;(Suppl 1 Proceedings of the International Conference on Human):I46.
14.
Colah RB, Gorakshakar AC, Nadkarni AH: Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: experiences from India. Indian J Med Res 2011;134:552-560.
15.
Aggarwal S, Phadke SR: Medical genetics and genomic medicine in India: current status and opportunities ahead. Mol Genet Genomic Med 2015;3:160-171.
16.
Bittles AH: Endogamy, consanguinity and community disease profiles. Community Genet 2005;8:17-20.
17.
Rosenberg NA, Mahajan S, Gonzales-Quevedo C, et al: Low levels of genetic divergence across populations of India. PLoS Genet 2006;2:e215.
18.
Ankala A, Tamhankar PM, Valencia CA, Rayam KK, Kumar MM, Hegde MR: Clinical applications and implications of common and founder mutations in Indian subpopulations. Hum Mutat 2015;36:1-310.
19.
Bhat BV, Babu L: Congenital malformations at birth - a prospective study from south India. Indian J Pediatr 1998;65:873-881.
20.
Jangra B, Singh M, Rattan KN, Kadian YS, Kaur A: Congenital anomalies in paediatric surgery in North India. Afr J Paediatr Surg 2014;11:39-43.
21.
Kalyani R, Bindra MS, Mahansetty H: Congenital malformations in perinatal autopsy: a two-year prospective study. J Indian Med Assoc 2013;111:89-93.
22.
Khurmi MS, Gupta M, Chaudhari G: Addressing the public health challenge of birth defects in India. Indian J Child Health 2014;1:95-98.
23.
Allagh KP, Shamanna BR, Murthy GV, Ness AR, Doyle P, Neogi SB, Pant HB; Wellcome Trust-PHFI Folic Acid project team: Birth prevalence of neural tube defects and orofacial clefts in India: a systematic review and meta-analysis. PLoS One 2015;10:e0118961.
24.
Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S: Down syndrome: an insight of the disease. J Biomed Sci 2015;22:41.
25.
Verma IC, Lall M, Dua Puri R: Down syndrome in India - diagnosis, screening, and prenatal diagnosis. Clin Lab Med 2012;32:231-248.
26.
Gourie-Devi M: Epidemiology of neurological disorders in India: review of background, prevalence and incidence of epilepsy, stroke, Parkinson's disease and tremors. Neurol India 2014;62:588-598.
27.
Agrawal D, et al: Study of incidence and prevalence of musculoskeletal anomalies in a tertiary care hospital of eastern India. J Clin Diagn Res 2014;8:AC04-AC06.
28.
Das SK, Ghosh B, Das G, Biswas A, Ray J: Movement disorders: Indian scenario: a clinico-genetic review. Neurol India 2013;61:457-466.
29.
Dutta UR, Rajitha P, Pidugu VK, Dalal AB: Cytogenetic abnormalities in 1162 couples with recurrent miscarriages in southern region of India: report and review. J Assist Reprod Genet 2011;28:145-149.
30.
Bhide P, Sagoo GS, Moorthie S, Burton H, Kar A: Systematic review of birth prevalence of neural tube defects in India. Birth Defects Res A Clin Mol Teratol 2013;97:437-443.
31.
Verma IC, Saxena R, Kohli S: Hemoglobinopathies in India - clinical and laboratory aspects. Clin Lab Med 2012;32:249-262.
32.
Ghosh K, Colah RB, Mukherjee MB: Haemoglobinopathies in tribal populations of India. Indian J Med Res 2015;141:505-508.
33.
Tamhankar PM, Agarwal S, Arya V, Kumar R, Gupta UR, Agarwal SS: Prevention of homozygous beta thalassemia by premarital screening and prenatal diagnosis in India. Prenat Diagn 2009;29:83-88.
34.
Munshi A, Anandraj MP, Joseph J, Shafi G, Anila AN, Jyothy A: Inherited hemoglobin disorders in Andhra Pradesh, India: a population study. Clin Chim Acta 2009;400:117-119.
35.
De M, Das SK, Bhattacharya DK, Talukder G: The occurrence of beta-thalassemia mutation and its interaction with hemoglobin E in the eastern India. Int J Hematol 1997;66:31-34.
36.
Dherai AJ: Inborn errors of metabolism and their status in India. Clin Lab Med 2012;32:263-279.
37.
Verma IC, Bijarnia-Mahay S, Jhingan G, Verma J: Newborn screening: need of the hour in India. Indian J Pediatr 2015;82:61-70.
38.
Roy A, Samanta T, Purkait R, Mukherji A, Ganguly S: Etiology, clinical spectrum and outcome of metabolic liver diseases in children. J Coll Physicians Surg Pak 2013;23:194-198.
39.
Agarwal SS, et al: Handigodu disease: a radiological study. A new variety of spondyloepi(meta)physeal dysplasia of the autosomal dominant type. Skeletal Radiol 1994;23:611-619.
40.
Agarwal SS, Phadke SR, Fredlund V, Viljoen D, Beighton P: Mseleni and Handigodu familial osteoarthropathies: syndromic identity? Am J Med Genet 1997;72:435-439.
41.
Stephen J, Girisha KM, Dalal A, Shukla A, Shah H, Srivastava P, Kornak U, Phadke SR: Mutations in patients with osteogenesis imperfecta from consanguineous Indian families. Eur J Med Genet 2015;58:21-27.
42.
Sharma S, Arya R, Raju KN, Kumar A, Scheper GC, van der Knaap MS, Gulati S: Vanishing white matter disease associated with ptosis and myoclonic seizures. J Child Neurol 2011;26:366-368.
43.
Upadhyay RP: An overview of the burden of non-communicable diseases in India. Iran J Public Health 2012;41:1-8.
44.
Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M: Rising prevalence of NIDDM in an urban population in India. Diabetologia 1997;40:232-237.
45.
Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasanna Kumar KM, Nair JD: High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001;44:1094-1101.
46.
Mohan V, Venkatraman JV, Pradeepa R: Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario. J Diabetes Sci Technol 2010;4:158-170.
47.
Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, Bleyl S, et al: Global implementation of genomic medicine: we are not alone. Sci Transl Med 2015;7:290ps13.
48.
Simon R, Roychowdhury S: Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013;12:358-369.
49.
Lim ET, et al; Sequencing Initiative Suomi (SISu) Project: Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet 2014;10:e1004494.
50.
Deelen P, et al: Improved imputation quality of low-frequency and rare variants in European samples using the ‘Genome of The Netherlands'. Eur J Hum Genet 2014;22:1321-1326.
51.
Tekola-Ayele F, Rotimi CN: Translational genomics in low- and middle-income countries: opportunities and challenges. Public Health Genomics 2015;18:242-247.
52.
Mori M. A, Lapunzina P, Delicado A, Nunez G et al: A prenatally diagnosed patient with full monosomy 21: ultrasound, cytogenetic, clinical, molecular, and necropsy findings. Am J Med Genet A 2004;127A:69-73.
53.
Reddy K. S: India's aspirations for universal health coverage. N Engl J Med 2015;373:1-5.
54.
Sharma AK: National rural health mission: time to take stock. Indian J Community Med 2009;34:175-182.
55.
Nandraj S, Khot A: Accreditation system for health facilities: challenges and opportunities. Econ Polit Wkly 2003;50:5251-5255.
56.
World Health Organization: Quality assurance in health laboratory services: a status report. New Delhi, World Health Organization Regional Office for South-East Asia, 2003 (SEA-HLM-354).
57.
Ghosh K, Mohanty D: Teaching of medical genetics in the medical colleges of India - way ahead. Indian J Hum Genet 2002;8:43-44.
58.
Pradhan S, Sengupta M, Dutta A, Bhattacharyya K, Bag S, Dutta C, Ray K: Indian genetic disease database. Nucleic Acids Res 2011;39(suppl 1):D933-D938.
59.
Indian Medical Council: Professional conduct, etiquette and ethics regulations. 2002.
60.
Ethical guidelines for biomedical research on human subjects. New Delhi, Indian Council of Medical Research, 2000.
61.
Ethical policies on the human genome, genetic research & services. National Bioethics Committee, Department of Biotechnology, Ministry of Science and Technology, Government of India, 2002.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.